• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

New Classification of triple negative breast cancer (TNBC) based on immune status with clinical characteristic

Research Project

Project/Area Number 17K10570
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field General surgery
Research InstitutionNational Cancer Center Japan

Principal Investigator

Kogawa Takahiro  国立研究開発法人国立がん研究センター, 東病院, 非常勤医員 (70444916)

Co-Investigator(Kenkyū-buntansha) 土井 俊彦  国立研究開発法人国立がん研究センター, 東病院, 科長 (20522907)
設楽 紘平  国立研究開発法人国立がん研究センター, 東病院, 医長 (20730419)
藤井 誠志  国立研究開発法人国立がん研究センター, 先端医療開発センター, ユニット長 (30314743)
原野 謙一  国立研究開発法人国立がん研究センター, 東病院, 医員 (80627258)
内藤 陽一  国立研究開発法人国立がん研究センター, 東病院, 医員 (90590373)
Project Period (FY) 2017-04-01 – 2022-03-31
Project Status Completed (Fiscal Year 2021)
Budget Amount *help
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Keywordsトリプルネガティブ乳がん / TIL / 亜分類 / TNBC / 免疫染色 / TILs / predictor / pCR / トリプルネガティブ乳癌 / 遺伝子発現 / 腫瘍浸潤リンパ球 / 免疫機能解析
Outline of Final Research Achievements

High levels of tumor-infiltrating lymphocytes (TILs) have been suggested as an indicator of anti-tumor immunity as a predictor of treatment response in breast cancer patients. In this study, immunohistologic assay (IHC) of TILs and their subsets will be performed to determine whether TIL is predictive of treatment response and prognosis. TNBC is a heterogeneous tumor subclassified by gene expression data. TNBC subclassification by IHC, TNBC is also a target for potential immune checkpoint inhibitor effects through TILs subsets. In addition to the TNBC subclassification using IHC, we will explore the emergence of targets that may benefit from checkpoint inhibitors.
High TIL and high ki-67 were the most predictive biomarkers for pCR in TNBC. Lack of Vimentin was correlated with high TIL, and it implicates that vimentin based on IHC could show Mesenchymal subtype. Further investigation to assess the microenvironment of tumor is needed to explore predictive biomarkers of pCR.

Academic Significance and Societal Importance of the Research Achievements

TNBCは比較的稀な乳がんであるが、遺伝性乳がん卵巣癌症候群のBRCA1遺伝子の変化との関わりが強いことなど、若年性乳がんでの発症が多い。AYA世代における乳がんは、結婚や出産などのライフイベントの多い時期であることからも、早急に対応が必要な疾患である。我々の研究はこのTNBCの亜分類を行い、将来的な個別化医療につながる研究となり、新薬開発にポジティブな影響を与える可能性がある。

Report

(6 results)
  • 2021 Annual Research Report   Final Research Report ( PDF )
  • 2020 Research-status Report
  • 2019 Research-status Report
  • 2018 Research-status Report
  • 2017 Research-status Report
  • Research Products

    (4 results)

All 2020 2019 2018

All Journal Article (2 results) (of which Peer Reviewed: 2 results,  Open Access: 1 results) Presentation (2 results)

  • [Journal Article] Use of Eribulin as an Earlier-Line Chemotherapy for Patients With HER2-negative Metastatic Breast Cancer2020

    • Author(s)
      Sumito Shingaki, Takahiro Kogawa, Mototsugu Shimokawa et al.
    • Journal Title

      Journal of Cancer

      Volume: 11(14) Issue: 14 Pages: 4099-4105

    • DOI

      10.7150/jca.37670

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer2018

    • Author(s)
      Shimokawa Mototsugu、Kogawa Takahiro、Shimada Takako、Saito Toshiaki、Kumagai Hozumi、Ohki Masafumi、Kaku Tsunehisa
    • Journal Title

      Journal of Cancer

      Volume: 9 Issue: 5 Pages: 872-879

    • DOI

      10.7150/jca.17664

    • Related Report
      2017 Research-status Report
    • Peer Reviewed
  • [Presentation] Baseline neutrophil to lymphocyte ratio is predictor of longer OS of metastatic BC patients treated with eribulin2019

    • Author(s)
      楠原正太, 古川孝広, 下川元継 ら
    • Organizer
      第17回日本臨床腫瘍学会学術集会
    • Related Report
      2019 Research-status Report
  • [Presentation] Revisit the risk factors of recurrence in node involved HER2-positive breast cancer.2019

    • Author(s)
      長谷川依子, 古川孝広, 下川元継 ら
    • Organizer
      第17回日本臨床腫瘍学会学術集会
    • Related Report
      2019 Research-status Report

URL: 

Published: 2017-04-28   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi